Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated May 16, 2023, discloses the results of Nuvation Bio Inc.'s 2023 Annual Meeting of Stockholders held on May 15, 2023. The Company is incorporated in Delaware and its Class A Common Stock and Redeemable Warrants trade on the New York Stock Exchange under the symbols NUVB and NUVB.WS, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders representing 94% of Class A Common Stock and 100% of Class B Common Stock (totaling 206,731,825 shares) were present, constituting a quorum. Three proposals were voted upon:
- Proposal 1: Election of Directors. Robert B. Bazemore, Jr. was elected as a Class A director with 140,642,378 votes FOR, 50,106,962 WITHHELD, and 14,982,485 BROKER NON-VOTES. Kim Blickenstaff was elected as a Class B director with 1,000,000 votes FOR and no withheld or non-votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote was 206,334,068 FOR, 118,931 AGAINST, and 278,826 ABSTAIN.
- Proposal 3: Executive Compensation Advisory Vote. Stockholders approved the compensation of named executive officers on an advisory basis. The vote was 153,714,329 FOR, 38,025,124 AGAINST, and 9,887 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting vote tallies.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 4, 2023, for detailed biographies of the elected directors and full executive compensation disclosures.
- Confirm the total number of outstanding shares and the record date of March 17, 2023, to validate the quorum calculation.
- Review the Company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.